Inflammatory bowel disease (IBD) constitutes a range of conditions, including Crohn's disease and ulcerative colitis. This article looks at therapeutic strategies and developments in the IBD area, focusing on antibody therapies that target #945;4-integrin or the cytokine TNF, and on other approaches that also involve blocking various cytokines or their receptors, or the NF-#954;B pathway.